Biotech · Private company · Columbia, MD, US
Intralytix, Inc.
Track this companyFree. Adds Intralytix, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials32 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- bacteriophagePhase 2 · ShigellosisClinicalTrials.gov · fetched Nov 12, 2026
- Bacteriophage preparationPhase 2 · Crohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- VRELysin™Phase 2 · Vancomycin-Resistant Enterococcal ColonizationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized SubjectsPHASE1_PHASE2 · SUSPENDED · started Oct 25, 2023ClinicalTrials.gov NCT05715619 · fetched Nov 12, 2026
- Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of ShigellosisPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 23, 2023ClinicalTrials.gov NCT05182749 · fetched Nov 12, 2026
- Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's DiseasePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 1, 2019ClinicalTrials.gov NCT03808103 · fetched Nov 12, 2026
NIH awards1
- Bacteriophage-based approach for managing Shigella infectionsFiscal year 2024 · $1.2MNIH RePORTER 5U01AI148054-05 · fetched Nov 12, 2026